Athena Countouriotis

Statistics

Publications

Citations

2.5K

H-Index

Active since

2006

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Pfizer (United States)

University of Bologna

Bristol-Myers Squibb (United States)

Bristol-Myers Squibb (Germany)

Athena Countouriotis is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, chronic myeloid leukemia therapy, and oncology pharmacotherapy.

Publications per year

2006–2014

Publications

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

Andreas Hochhaus, Hagop M. Kantarjian, Michele Baccarani et al. · Blood · 2006 · 609 citations · Full text

Medicine, Hematology, Oncology +14

Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial

Jörge E. Cortes, Dong‐Wook Kim, Hagop M. Kantarjian et al. · Journal of Clinical Oncology · 2012 · 469 citations

Medicine, Pharmacology, Pharmacotherapy +11

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial

Hagop Kantarjian, Ricardo Pasqüini, Nelson Hamerschlak et al. · Blood · 2007 · 378 citations · Full text

Medicine, Hematology, Oncology +5

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

Andreas Hochhaus, Michele Baccarani, Michael W. Deininger et al. · Leukemia · 2008 · 354 citations

Medicine, Hematology, Oncology +13

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

H. Jean Khoury, Jörge E. Cortes, Hagop M. Kantarjian et al. · Blood · 2012 · 318 citations · Full text

Medicine, Hematology, Oncology +6

1–5 of 13